First experience with a thermal-sprayed silver oxide-containing hydroxyapatite coating implant in two-stage total hip arthroplasty for the treatment of septic arthritis with hip osteoarthritis: A case report

Akira Hashimoto, Motoki Sonohata, Masaru Kitajima, Shunsuke Kawano, Shuichi Eto, Masaaki Mawatari

Department of Orthopaedic Surgery, Faculty of Medicine, Saga University, Nabeshima 5-1-1, Saga 849-8501, Japan

A R T I C L E   I N F O

Article history:
Received 29 October 2020
Received in revised form 8 November 2020
Accepted 8 November 2020
Available online 11 November 2020

Keywords:
Septic arthritis of the hip
Silver
Total hip arthroplasty

A B S T R A C T

INTRODUCTION: Septic arthritis of the hip joint in adults is a rare and potentially devasting disease. To the best of our knowledge, there have been no reports of two-stage total hip arthroplasty (THA) for the treatment of septic arthritis of the hip joint with a cementless hip implant that has antibacterial properties.

PRESENTATION OF CASE: We present a case of two-stage THA with a thermal-sprayed silver oxide-containing hydroxyapatite coating (Ag-HA) implant to treat septic arthritis of the hip joint with hip osteoarthritis in an 80-year-old woman. There was no complication or recurrence at 28 months follow-up after 2nd-stage operation.

DISCUSSION: Ag-HA implants were found to have antibacterial activity within the subcutaneous tissues and bone, osteoconductive properties, and no adverse reactions in vivo. Moreover, no adverse events due to silver were reported in a clinical or radiographic study.

CONCLUSION: To further reduce infection after two-stage THA for septic arthritis of the hip joint, antibacterial implants, such as an Ag-HA implant, may be used.

© 2020 The Authors. Published by Elsevier Ltd on behalf of JJS Publishing Group Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

Septic arthritis of the hip joint (SAHJ) in adults is a rare and potentially devasting disease [1]. The duration of symptoms is important for the selection of treatment [1]. Symptoms with an early onset can be treated with open or arthroscopic debridement [1]. Radical treatment is required for patients with prolonged symptoms or radiological destruction of the hip joint [1,2]. The conventional treatment for SAHJ is Girdlestone arthroplasty [3]. Currently, two-stage total hip arthroplasty (THA) with an interval antibiotic-loaded cement spacer is performed for the treatment of SAHJ [1,2]. However, there have been no reports of two-stage THA to treat SAHJ with a cementless hip implant that has antibacterial properties. Silver (Ag) is a well-known antibacterial agent with broad-spectrum activity, less bacterial resistance than that of antibiotics, and low toxicity toward humans [4]. In this case report, we report on a patient with SAHJ and hip osteoarthritis treated with two-stage THA using a thermal-sprayed silver oxide-containing hydroxyapatite coating (Ag-HA) implant, performed by an experienced orthopedic surgeon. This case was reported according to the SCARE criteria [5].

2. Case presentation

An 80-year-old woman presented to our hospital with severe right hip pain that had been worsening for 7 days. Her initial temperature, white blood cell (WBC) count, and C-reactive protein (CRP) were 35.8 °C, 6700/mm³, and 34.3 mg/dl, respectively. The initial blood culture revealed the presence of *Micromonas micros*. Radiography revealed osteoarthritis of the right hip joint (Fig. 1-a). Contrast-enhanced computed tomography showed destruction of the right femoral head and increased joint fluid in the right hip (Fig. 2). She was diagnosed as having septic shock associated with acute septic arthritis of the right hip joint. Her medical history included bilateral osteoarthritis of the hip joints, and she underwent left cementless THA (Fig. 1-a). The patient had no relevant drug history, family history (including any relevant genetic information), or psychosocial history. The findings and management...
Two-stage operations were caused by drug eruptions attributed to amoxicillin. The WBC count and CRP before the 2nd-stage operation was 4400/mm³ and 0.22 mg/dl, respectively.

In the 2nd-stage operation, a preformed antibiotic-loaded cement spacer was removed, and debridement of the necrotic and ischemic tissue was performed. Synovial fluid was obtained for culture. After a high-pressure pulsatile lavage with 9 L of lactated Ringer solution, the hips were reconstructed using the cementless implants. The acetabular component was AG-PROTEX cup (Kyocera, Tokyo, Japan). The femoral component was AG-PROTEX stem (Kyocera, Tokyo, Japan) (Fig. 3). The operative time for the 2nd stage was 65 min. The total blood loss during the 2nd-stage operation was 550 mL (intraoperative blood loss, 440 mL; postoperative blood loss, 110 mL). In the 2nd-stage operation, cultures of the hip joint fluid were negative. The suction drain was removed 2 days after the 2nd-stage operation as per routine. Antibiotic administration duration after the 2nd-stage operation was 85 days (intravenous cefazolin for 1 day followed by oral clindamycin or 84 days). Walking training was started without limitation of weight-bearing within the allowable pain range beginning 2 days after surgery.

The follow-up duration after the 2nd-stage operation was 28 months. There was no complication or recurrence after 2nd-stage operation. WBC count and CRP at final follow-up were 2600/mm³ and 0.03 mg/dl, respectively. Plain radiograph at final follow-up showed no loosening around acetabular and femoral component (Fig. 1-c). The patient was well and showed agreement with the positive results.

The study protocol adhered to the ethical guidelines of the 1975 Declaration of Helsinki, and the study was approved by the institutional review board. The patient was informed that this case study would be submitted for publication, and she provided consent.

3. Discussion

SAHJ commonly occurs among children and is relatively uncommon among adults. The incidence in adults is 2–10 per 100,000 person-years [6]. Risk factors of septic arthritis include age, rheumatoid arthritis, diabetes mellitus, and skin infection [7]. The common causative organisms of septic arthritis are Staphylococcus aureus and S. pyogenes [8].

Arthroscopic debridement is the current standard for early onset of SAHJ without extra-articular abscess formation and advanced osteochondral lesions owing to the lesser degree of invasiveness and shorter hospital stays than are associated with open debridement [1,9]. In progressed SAHJ, both infection control and treatment of destructed joint are needed. Previous studies reported direct THA, Girdlestone arthroplasty, THA after Girdlestone arthroplasty, and two-stage THA with an interval antibiotic-loaded cement spacer for the treatment of SAHJ [2,3,10,11]. Direct THA...
strated that the use of cementless implants was effective in the 2-stage surgery of SAHJ and periprosthetic THA infections [1]. Recent research also revealed that cementless implant or cement implant with antibiotic-loaded bone cement in the 2-stage surgery of periprosthetic THA infections was not associated with rate of infection recurrence [12].

While a risk of infection recurrence after a two-stage THA remains, recent studies reported the presence of bacteria within the bone tissue in an osteomyelitis model [12,13]. Therefore, in addition to a thorough two-stage THA, the Ag-HA coating implant was selected to further reduce the risk of infection recurrence.

A silver-coated mega-prosthesis has been used previously; however, concentrated silver is toxic to osteoblasts, suppresses ossification, and implicates in osteolysis and postoperative prosthesis loosening [14–16]. The maximum amount of silver contained in the Ag-HA implant used in the current study was 2.9 mg, which is considerably lower than that in a silver-coated megaprosthesis [17]. In basic studies, Ag-HA implants were found to have antibacterial activity within the bone, osteoconductive properties, and no adverse reactions in vivo [18–20]. Moreover, no adverse events due to silver were reported in a clinical and radiographic study [21]. Besides a thorough two-stage THA, Ag-HA implants may be particularly effective for patients with a high risk of infection, such as our case. However, a larger sample of patients with longer follow-up is required to confirm the safety and efficacy of Ag-HA implants.

4. Conclusion

This case demonstrated successful infection control at the 28-month follow-up. To further reduce the infection after the two-staged THA for SAHJ, antibacterial implants, such as Ag-HA implants, may be used; however, long-term studies with additional cases of Ag-HA implants are needed.

Declaration of competing interest

The authors declare that there is no conflict of interest regarding the publication of this article.

Funding

This research did not receive any specific grant from funding agencies in either the public, commercial, or not-for-profit sectors.

Ethical approval

The study protocol adhered to the ethical guidelines of the 1975 Declaration of Helsinki. In addition, the study was approved by the institutional review board of our institute.

Consent

Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal on request.

Author contribution

Akira Hashimoto: Manuscript writing; Original draft preparation
Motoki Sonohata: Corresponding
Masaru Kitajima: Manuscript writing; Review and Editing
Shunsuke Kawano: Manuscript writing; Review and Editing
Shuichi Eto: Manuscript writing; Review and Editing

Fig. 3. Silver-containing hydroxyapatite coating implant.
Masaaki Mawatari: Supervision

Registration of research studies

This case report is not applicable for registration.

Guarantor

Motoki Sonohata.

Provenance and peer review

Not commissioned, externally peer-reviewed.

Acknowledgment

We would like to thank Editage (www.editage.com) for English language editing.

References

[1] C.L. Romanò, D. Romanò, E. Meani, N. Logoluso, L. Drago, Two-stage revision surgery with preformed spacers and cementless implants for septic hip arthritis: a prospective, non-randomized cohort study, BMC Infect. Dis. 11 (2011) 129.
[2] K. Anaagnostakos, L. Duchow, K. Koch, Two-stage protocol and spacer implantation in the treatment of destructive septic arthritis of the hip joint, Arch. Orthop. Trauma Surg. 137 (2016) 899–906.
[3] G.R. Girdlestone, Acute pyogenic arthritis of the hip: an operation giving free access and effective drainage, Clin. Orthop. Relat. Res. 466 (2008) 258–263.
[4] S.A. Brennan, C. Ni Phoghlú, B.M. Devitt, P.J. O’Mahony, D. Brabazon, A. Walsh, Silver nanoparticles and their orthopaedic applications, Bone Joint J. 97-B (2015) 582–589.
[5] R.A. Agha, M.R. Borrelli, R. Farwana, K. Koshy, A. Fowler, D.P. Orgill, For the SCARE Group, The SCARE 2018 statement: updating consensus surgical case report (SCARE) guidelines, Int. J. Surg. 60 (2018) 132–136.
[6] D.L. Goldenberg, Septic arthritis, Lancet 351 (1998) 197–202.
[7] C.J. Kaanders, D. Van Schaardenburg, P. Krijnen, J.D. Habbema, M.A. van de Laar, Risk factors for septic arthritis in patients with joint disease. A prospective study, Arthritis Rheum. 38 (1995) 1819–1825.
[8] M. García-Aria, A. Balsa, E.M. Mola, Septic arthritis, Best Pract. Res. Clin. Rheumatol. 25 (2011) 407–421.
[9] A.M. El-Sayed, Treatment of early septic arthritis of the hip in children: comparison of results of open arthrotomy versus arthroscopic drainage, J. Child. Orthop. 2 (2008) 229–237.
[10] J.B. Jupiter, A.W. Karchne, J.D. Lowell, W.H. Harris, Total hip arthroplasty in the treatment of adult hips with current or quiescent sepsis, J. Bone Joint Surg. Am. 63 (1981) 194–200.
[11] S. Bebe, M. Sonohata, M. Kitajima, S. Kawano, M. Mawatari, Total hip arthroplasty following Girdlestone arthroplasty, J. Orthop. Sci. 23 (2018) 532–537.
[12] J. Sanchez-Sotelo, D.J. Berry, A.D. Hanssen, M.E. Cabanela, Midterm to long-term followup of staged reimplantation for infected hip arthroplasty, Clin. Orthop. Relat. Res. 467 (2009) 219–224.
[13] K.L. de Mesity Bentley, R. Trombetta, K. Nishitani, S.N. Bello-trizarry, M. Ninomiya, L. Zhang, et al., Evidence of Staphylococcus aureus deformation, proliferation, and migration in Canalulci of live cortical bone in murine models of osteomyelitis, J. Bone Miner. Res. 32 (2017) 985–990.
[14] B. Hussmann, I. Johann, M.D. Kauther, S. Landgraeber, M. Jäger, S. Lendemans, Measurement of the silver ion concentration in wound fluids after implantation of silver-coated megaprostheses: correlation with the clinical outcome, Biomed Res. Int. 2013 (2013), 763096.
[15] G.A. Fielding, M. Roy, A. Bandyopadhyay, S. Boie, Antibacterial and biological characteristics of silver containing and stentron doped plasma sprayed hydroxyapatite coatings, Acta Biomater. 8 (2012) 3144–3152.
[16] C.E. Albers, W. Hofstetter, K.A. Siebenrock, R. Landmann, F.M. Klenke, In vitro cytotoxicity of silver nanoparticles on osteoblasts and osteoclasts at antibacterial concentrations. Nanotoxicology 7 (2013) 30–36.
[17] J. Hardes, H. Ahrens, G. Gebert, A. Streitbuerger, H. Buerger, M. Eeren, et al., Lack of toxicological side-effects in silvercoated megaprostheses in humans, Biomaterials 28 (2007) 2869–2875.
[18] T. Akiyama, H. Miyamoto, Y. Yonekura, M. Tsukamoto, Y. Ando, Noda, et al., Silver oxide-containing hydroxyapatite coating has in vivo antibacterial activity in the rat tibia, J. Orthop. Res. 31 (2013) 1195–1200.
[19] Y. Yonekura, H. Miyamoto, T. Shimazaki, Y. Ando, I. Noda, M. Mawatari, et al., Osteoconductivity of thermal-sprayed silver-containing hydroxyapatite coating in the rat tibia, J. Bone Joint Surg. Br. 93 (2011) 644–649.
[20] T. Akiyama, H. Miyamoto, Y. Ando, I. Noda, S. Eto, T. Akiyama, et al., Acute and subacute toxicity in vivo of thermal-sprayed silver containing hydroxyapatite coating in rat tibia, Biomed Res. Int. 2014 (2014), 902343.
[21] S. Eto, S. Kawano, A. Someya, H. Miyamoto, M. Sonohata, M. Mawatari, First clinical experience with thermal-sprayed silver oxide-containing hydroxyapatite coating implant, J. Arthroplasty 31 (2016) 1498–1503.

Open Access

This article is published Open Access at sciedirect.com. It is distributed under the lJSCR Supplemental terms and conditions, which permits unrestricted non commercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.

437